CSBio CSBio

X
[{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Lava Therapeutics"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Novo Ventures","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Lava Therapeutics"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Lava Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"$419.5 million","upfrontCash":"$4.5 million","newsHeadline":"Genmab and Synaffix Enter into License Agreement for ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"$5.0 million","newsHeadline":"Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Peptide","graph2":"ISA Pharmaceuticals"},{"orgOrder":0,"company":"AIMM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIMM Therapeutics Presents Preclinical Data on its Four Oncology Therapies at AACR\u2019s Annual Meeting Session on Antibody Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AIMM Therapeutics"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"LUMICKS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUMICKS Enters Collaboration with Glycostem to Enhance NK cell-Mediated Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Glycostem Therapeutics"},{"orgOrder":0,"company":"Sapreme technologies","sponsor":"Aglaia Oncology Funds","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Sapreme technologies"},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Oost NL","pharmaFlowCategory":"D","amount":"$17.4 million","upfrontCash":"Undisclosed","newsHeadline":"Pleco Therapeutics Announces Final Close of its Series A Financing Raising \u20ac17.3m to Progress its Novel Plecoid\u2122 Product in Acute Myeloid Leukaemia to Regulatory Filing in USA and EU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Pleco Therapeutics"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$335.0 million","upfrontCash":"$40.0 million","newsHeadline":"Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRP\u03b1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sairopa"},{"orgOrder":0,"company":"TerThera","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"TerThera"},{"orgOrder":0,"company":"TerThera","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radiopharm Theranostics Expands Supply Agreement with TerThera for Terbium-161 Isotope Use in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"TerThera"},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Tagworks Pharmaceuticals"},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Tagworks Pharmaceuticals"},{"orgOrder":0,"company":"Immunorizon","sponsor":"Purple Biotech","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"$3.5 million","newsHeadline":"Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Immunorizon"},{"orgOrder":0,"company":"Tessellate BIO","sponsor":"BioGeneration Ventures","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Tessellate BIO Emerges from Stealth","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Tessellate BIO"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The financing will be used to focun on company's lead program that targets the DNA damage response (DDR) and in particular cancers that depend on Alternative Lengthening of Telomeres (ALT).

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: BioGeneration Ventures

            Deal Size: $8.4 million Upfront Cash: Undisclosed

            Deal Type: Financing October 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, TerThera will supply Radiopharm with Terbium-161 and Tb-161 isotope will be linked to a proprietary mAb to form RAD 402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression in patients with advanced prostate cancer.

            Lead Product(s): RAD 402,Terbium-161

            Therapeutic Area: Oncology Product Name: RAD 402

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Radiopharm Theranostics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will support the advancement of TGW101, a click-cleavable ADC targeting tumor-associated glycoprotein 72, and the company’s proprietary Click-to-Release platform.

            Lead Product(s): TGW101

            Therapeutic Area: Oncology Product Name: TGW101

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $65.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will support the advancement of TGW101, Tagworks' lead click-cleavable ADC program targeting tumor-associated glycoprotein 72 (TAG72), and the company's proprietary Click-to-Release platform.

            Lead Product(s): TGW101

            Therapeutic Area: Oncology Product Name: TGW101

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $65.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, Janssen has chosen a lead gamma-delta T-cell engager bispecific antibody candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings for the treatment of cancer.

            Lead Product(s): Bispecific Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement aims to supply Tb-161 for RAD 602, a radiotherapeutic that is being developed by Radiopharm to target protein tyrosine phosphatase mu (PTPmu or PTPμ) for treatment of brain cancers.

            Lead Product(s): RAD602

            Therapeutic Area: Oncology Product Name: RAD602

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Radiopharm Theranostics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The acquisition will provide Purple Biotech with an expanded portfolio of investigational tri-specific antibody compounds that target multiple antigens and offer the potential to further expand to additional targets.

            Lead Product(s): Tri-specific Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Purple Biotech

            Deal Size: $101.0 million Upfront Cash: $3.5 million

            Deal Type: Acquisition February 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers. It plays a crucial role in tumor survival and spread.

            Lead Product(s): ISA103,Undisclosed

            Therapeutic Area: Oncology Product Name: ISA103

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Cancer Focus Fund

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding January 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Exelixis and Sairopa will develop ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα. ADU-1805 is active against all human alleles of SIRPα, which may allow it to address a broader patient population than other SIRPα-directed therapies.

            Lead Product(s): ADU-1805

            Therapeutic Area: Oncology Product Name: ADU-1805

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Exelixis

            Deal Size: $335.0 million Upfront Cash: $40.0 million

            Deal Type: Collaboration November 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funds will be used to complete development and commercialise the Company’s novel lead Plecoid™ Product, PTX-061, to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML).

            Lead Product(s): PTX-061

            Therapeutic Area: Oncology Product Name: PTX-061

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oost NL

            Deal Size: $17.4 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY